For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/courses/personalizing-care-identifying-the-right-patients-for-new-treatments-10268

Summary
Dr. Genevieve Neal-Perry and Dr. Andrea Singer focus on practical strategies in the personalized management of menopausal vasomotor symptoms (VMS). The discussion covers the importance of routine and individualized screening for VMS, with attention to healthcare disparities and the diverse ways menopause is discussed and experienced across populations, before covering patient selection criteria for newer non-hormonal treatments.

This podcast was recorded and is being used with permission of the presenters.

Learning Objectives

• Integrate routine and individualized screening methods to identify patients with menopausal VMS, with attention to healthcare disparities
• Integrate new and emerging agents into the treatment of women with menopausal VMS, based on patient characteristics and preference

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at [email protected].

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is supported in part by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/courses/targeting-cause-emerging-therapies-menopausal-vms-10267

Summary
This enduring podcast activity explores groundbreaking advancements in the treatment of menopausal vasomotor symptoms (VMS), emphasizing non-hormonal therapies. Dr. Andrea Singer and Dr. Genevieve Neal-Perry discuss the underlying biology of menopause, particularly the role of neurokinin (NK) receptors, and introduces the science behind new therapeutic agents, as well as their clinical trial data.

This podcast was recorded and is being used with permission of the presenters.

Learning Objective
Discuss the clinical trial data for new and emerging non-hormonal therapies

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at [email protected].

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is supported in part by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:

1. Antihypertensive Medication Timing and Cardiovascular Events and Death The BedMed Randomized Clinical Trial JAMA 2025.  Discussion by:
Guest:
Susan Kuchera, MD
Director of the Family Medicine Residency Program
Jefferson Health - Abington

2. Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy. 2025.  Discussion by:
Guest:
Eden Miller, MD
Diabetes and Obesity Specialist
Bend, Oregon

3. As-Needed Albuterol–Budesonide in Mild Asthma. The New England Journal of Medicine.  Discussion by:
Guest:
Dylan Selden, MD
Resident– Family Medicine Residency Program 
Jefferson Health – Abington

Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. 

This Podcast Episode does not offer CME/CE Credit. 

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/courses/strategies-and-real-world-impact-of-the-stimulant-crisis-10220

Summary
The stimulant medication shortage has introduced new challenges in managing ADHD, affecting both patients’ access to essential treatments and clinicians’ ability to provide consistent care. In this PsychTalk podcast/webcast episode, Drs. Gregory Mattingly and Roger McIntyre explore the impact of these shortages, particularly on cognitive functioning, treatment continuity, and daily life for individuals with ADHD. Their discussion also examines stimulant misuse and diversion, looking at trends in medication sourcing, formulations most susceptible to abuse, and strategies to reduce the risk of misuse. By the end of the episode, learners will be equipped with timely insights and real-world tools to optimize ADHD management amid evolving supply and safety challenges.

This podcast was recorded and is being used with permission of the presenters.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

• Describe the impact of stimulant shortages on individuals with ADHD
• Incorporate best-practice clinical strategies to minimize the risk of stimulant misuse in the treatment of ADHD

This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at [email protected].

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This activity is not supported by an educational grant.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

http://mycme.com/courses/the-cognitive-side-of-major-depressive-disorder-10221

Summary
Despite significant improvements in mood symptoms, many patients with MDD continue to experience persistent residual symptoms—particularly cognitive impairments—that hinder full functional recovery. In this PsychTalk podcast/webcast episode, Drs. Gregory Mattingly and Roger McIntyre discuss the often-overlooked role of cognitive dysfunction in MDD recovery, highlighting how these impairments correlate strongly with reduced workplace productivity, social withdrawal, and elevated relapse risk, ultimately impeding long-term outcomes. Their conversation provides listeners with an in-depth understanding of the presentation of cognitive impairment and residual symptoms in MDD, as well as strategies to foster resilience, enhance patient engagement, and promote functional recovery.

This podcast was recorded and is being used with permission of the presenters.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

• Recognize the clinical significance of residual symptoms in MDD, with a focus on cognitive impairment, and their impact on patient functioning and treatment outcomes

This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.25 hours of pharmacology).

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/the-latest-data-in-ckd-progression-10197

Summary
Emerging evidence highlights the potential of GLP-1 receptor agonists (GLP-1 RAs) to slow CKD progression and reduce cardiovascular and kidney-related mortality in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). Yet, despite updated guidelines, these therapies remain underused. This program will explore the latest clinical data supporting the role of GLP-1 RAs in risk mitigation and provide practical strategies for implementing guideline-based treatment to reduce cardio-renal risk and improve outcomes in patients with T2D and CKD.

This podcast was recorded and is being used with permission of the presenters.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

• Discuss emerging data on GLP-1 RA therapy for CKD progression in T2D
• Implement guideline-based care to minimize CV risk and CKD progression

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at [email protected].

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This activity is supported by an educational grant from Novo Nordisk.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:

1. Effects of Combining Coronary Calcium Score With Treatment on Plaque
Progression in Familial Coronary Artery Disease A Randomized Clinical Trial JAMA 2025. Discussion by:
Guest:
Michael J. Blaha, MD, MPH
Professor of Cardiology and Epidemiology and presently serves as the
Director of Clinical Research for the Johns Hopkins Ciccarone Center for the
Prevention of Cardiovascular Disease
Director of the Cardiometabolic Clinic
Program Director for the Preventive Cardiology Fellowship.

2. Creatine monohydrate pilot in Alzheimer’s: Feasibility, brain creatine, and cognition. Alzheimer’s Dement. 2025. Discussion by:
Guest:
Michael Devano, DO 
Attending Family Physician 
Christiana Care Health System

3. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. The New England Journal of Medicine. Discussion by:
Guest:
Joseph Gonnella, MD 
Resident– Family Medicine
Residency Program, Jefferson Health – Abington

Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. 

This Podcast Episode does not offer CME/CE Credit. 

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/answers-in-chronic-spontaneous-urticaria-10190

Summary
In this short CE/CME activity, moderator Dr. Brad Glick works with dermatology expert Dr. Gil Yosipovitch to answer your top questions regarding chronic spontaneous urticaria, as gathered from the 2025 NACE Conversations in Dermatology symposium. Questions cover diagnosis, treatment individualization, and more!

Learning Objectives
At the conclusion of this activity, participants should be better able to:

• Assess the disease burden and impact on QoL in patients with CSU
• Evaluate current and emerging therapies for CSU

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at [email protected].

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This activity is supported by an independent educational grant from Sanofi and Regeneron Pharmaceuticals.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/copd-inflammation-exacerbations-your-questions-answered-10143

Summary
Rejoin the conversation on COPD, inflammation, and new and emerging agents as two of our expert faculty come together to answer your top questions. Questions submitted from the recent Conversations in Primary Care live virtual symposia guide the discussion as we dig a bit deeper on type 2 inflammation, changes in COPD management, and new and emerging agents – including recently approved biologic agents – for COPD.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

• Review the relationship between inflammation, exacerbation, and disease progression in COPD, noting different inflammatory endotypes of patients with COPD
• Discuss recent evidence surrounding the use of biologic agents in the management of patients with COPD and type 2 inflammation
• Integrate current guidelines with clinical data on new and emerging agents for the management of COPD, distinguishing patients with and without markers of type 2 inflammation

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at [email protected].

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.